Vuzix announced the company has expanded its sales footprint in the Biopharmaceutical industry by way of recent M300 Smart Glasses deliveries to a Fortune-100 pharmaceutical company. This next stage represented revenues in the low six figures for Vuzix. These M300's will be deployed across four continents through numerous use cases including research and development, manufacturing, and logistics. This is the latest in a series of pilots and production deployments in Biopharma and Life Sciences.
During the first half of 2017, Vuzix worked closely with its VIP software partners as well as many of the Biopharma and Life Sciences companies themselves to seed proof of concept and pilot programs that are now taking root. These end customers have completed several pilot programs and are now placing follow-up orders in volume. This conversion to commercial volume deployments is also occurring across other market verticals for Vuzix products, as the sales team focuses on direct relationships with the end user clients while concurrently expanding the software application ecosystem.
"We continue to have success with proof-of-concept programs moving towards broader deployment across a variety of different industries," said Paul Travers, President and Chief Executive Officer at Vuzix. "The successes of initial implementations of the M300 has resulted in a growing pipeline and follow-on orders paving the way for significant adoption within the pharma and life sciences industries as we move into 2018."